Pharmacy Practice Faculty Publications

Document Type

Article

Publication Date

11-14-2020

Journal Title

Pharmacy (Basel)

ISSN

2226-4787

Volume

8

Issue

4

DOI

10.3390/pharmacy8040215

PubMed ID

33202616

PubMed Central® ID

PMC7712908

Abstract

Insulin therapy is frequently required to achieve glycemic targets (A1c) in type 2 diabetes (T2D); however, clinicians and patients face barriers with the complexities of multiple daily injection regimens. Patch-like wearable insulin devices, such as V-Go, may simplify and optimize this complexity. This study evaluated the change in A1C and insulin total daily dose (TDD) in a suboptimally-controlled (not achieving A1C targets) T2D population after switching to V-Go. A retrospective chart analysis at a diabetes clinic was performed to evaluate change in A1c measurements from baseline (V-Go initiation) to end of study observation. Of the 139 patients enrolled, A1C significantly decreased from baseline (-1.5 ± 1.79%;

Keywords

V-Go, glycemic control, hemoglobin A1c, insulin, type 2 diabetes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.